A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease
Celiac Disease
About this trial
This is an interventional treatment trial for Celiac Disease focused on measuring celiac, gluten, Interleukin 15 (IL-15), AMG 714, gluten challenge
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of celiac disease by intestinal biopsy at least 12 months prior to screening
- On a gluten-free diet for at least 12 months
- Negative celiac serology
- Avoidance of pregnancy
Exclusion Criteria:
- Severe complications of celiac disease, such as refractory celiac disease
- Celiac symptoms
- Other concomitant autoimmune disease
- Chronic, active gastrointestinal disease
- Infections, concomitant diseases
- Prohibited medications
Sites / Locations
- ODL
- Tampere University Hospital
- CRST
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
AMG 714 150 mg
AMG 714 300 mg
Placebo
Participants received 150 mg AMG 714 via subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
Participants received 300 mg AMG 714 via subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
Participants received placebo subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).